Track LGVN and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Longeveron LLC
Life Science & Technology Park, Miami, FL, United States, 33136
IPO
2021
Employees
38
Industry
Biotechnology
Sector
Healthcare
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20254-4
0
Analyst Ratings
3 analysts covering
Buy100%recommend buy
Buy
3
Hold
0
Sell
0